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Associations between use of cyclosporine-sparing agents and over the past decade, exploiting the interactions with
outcome in kidney transplant recipients. cyclosporine metabolism to reduce the dose and thereby
Background. Diltiazem, widely used as a cyclosporine-spar- cost of cyclosporine [1]. The main agent used has beening agent, has been suggested to confer a benefit on graft and
diltiazem. An effect of diltiazem on graft outcome haspatient outcome in kidney transplantation related to immuno-
been suggested, mediated either by direct immunosup-modulatory properties. Use of cyclosporine-sparing agents
(CsSpA) is routinely recorded by the Australia & New Zealand pressive effects leading to lower rejection rates [2] or as
Dialysis and Transplant (ANZDATA) Registry, and we used a protector of cell integrity, in particular reducing the
these data to examine the associations between CsSpA use
rate of delayed graft function [3, 4].and outcomes.
We used data from the Australia & New ZealandMethods. Graft and patient survival were analyzed for a
cohort of 3913 people who received kidney transplants in Aus- Dialysis and Transplant Registry (ANZDATA) to ex-
tralia or New Zealand between 1 April 1993 and 30 March amine the association of CsSpA use with long-term graft
2001. Patients were followed to death or loss of graft function. and patient outcomes in renal transplants receiving cyclo-
Graft and patient survival analyses were performed using Cox
sporine-based immunosuppression.proportional hazards models, including a time varying covari-
ate for CsSpA use in analyses of graft failure. Occurrence of
delayed graft function (DGF) and acute rejection also were
METHODSexamined as secondary outcomes.
Results. There was no difference in patient survival in the ANZDATA collects information on all cases of end-
first 12 months post transplantation, but from 12 months on- stage renal disease (ESRD) in Australia and New Zealand.wards there is a survival advantage associated with CsSpA
Data are collected from all dialysis and transplant unitsuse among cadaveric donor (CD) recipients in both univariate
in Australia and New Zealand every six months. For trans-hazard ratio (HR) 0.56, 95% CI 0.41 to 0.76, P  0.001 and
multivariate (HR 0.56, 95% CI 0.40 to 0.79, P 0.001) analyses. plant recipients this includes age and demographic infor-
This was consistent across subgroups examined. Lower rates mation, and information about the transplant period (to-
of early graft loss (censored for death) were associated with
tal ischemic time, recipient cytomegalovirus (CMV) andCsSpA use [odds ratio (OR) 0.61, 95% CI 0.50 to 0.75, P 
Epstein-Barr virus (EBV) status and whether they are0.0001]. Lower rates of use of antibody therapy for rejection
also were observed, but not lower rates of biopsy-proven rejec- recipients of an organ from a cadaveric donor (CD) or
tion. living donor (LD). Immunosuppressive drugs, body weight
Conclusions. CsSpA use was associated with improved pa- and serum creatinine are collected at 1, 2, 3, 6 and 12tient mortality after kidney transplantation. Whether this was
months, and yearly thereafter. Use and type of CsSpAa direct drug effect or due to other factors associated with
were collected from 1989, but from 1994 this was codeddiltiazem use cannot be inferred directly from these data, al-
though several plausible mechanisms exist which might medi- simply as a yes/no response as over 99% of respondents
ate a diltiazem effect. from 1989 to 1993 used diltiazem. Episodes of acute
rejection within six months of transplant date have been
collected since 1 April 1997, and (where biopsy-proven)Cyclosporine sparing agents (CsSpA) have been widely
were classified by the caring center into “cellular” “vas-used in renal transplantation in Australia and New Zealand
cular” and “glomerular” types on a three point scale: mild,
moderate, or severe.
Key words: diltiazem, kidney transplantation, cadaveric organ recipi- Information about co-morbidities is collected for each
ent, graft survival, nephrotoxicity. patient at time of entry into the ESRD program. These
include coronary artery disease, lung disease, peripheralReceived for publication November 12, 2001
Accepted for publication February 5, 2002 vascular disease and diabetes (coded by the treating phy-
sician as yes, suspected or no) and hypertension and 2002 by the International Society of Nephrology
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cigarette smoking. “Suspected” was pooled with the RESULTS
“yes” for analyses. The use of CsSpA increased progressively from its
The outcome of grafts performed was examined using introduction in 1988 to 1993, but has been steady since
survival analysis, comparing recipients of CsSpA with then (Fig. 1).
non-recipients. Transplant centers were arbitrarily classi- During the period 1 April 1993 to 31 March 2001 there
fied into “routine” centers (those where 25% of all were 4629 kidney transplants performed. Multiple organ
grafts over this period received a CsSpA) and “non- transplants (159) and recipients less than 18 years (276)
routine” centers. Only grafts performed after 01 April were excluded. Others were excluded because they did
1993 were used for analysis, as CsSpA usage rates were not receive cyclosporine-based immunosuppression (262)
stable after that time. Only those given cyclosporine- or the transplant was performed overseas (19), leaving
3913 available for analysis. Of these, 2901 (74%) werebased immunosuppression were examined, and recipi-
from cadaveric donors. 3399 were first grafts (87%) in-ents of multiple organ grafts were excluded. Follow-up
cluded 927 from living donors (27% of first grafts). Overwas to 31 March 2001. Outcome events were loss of
the period of follow-up (median 3.1 years, aggregate 23908graft function (defined as need for dialysis therapy or
person-years) there were 246 deaths with a functioningre-transplantation), death (with functioning graft) or loss
graft and 560 graft failures (including 231 in the first 3to follow-up. Secondary analyses were performed using
months). Grafts lost to follow-up numbered 38 (1%).the occurrence of rejection and delayed graft function
(DGF) as end points. DGF was defined (by the Registry)
Prevalence of CsSpA useas the occurrence of dialysis greater than 24 hours post-
There was substantial variability in the rate of CsSpAtransplantation in a graft that subsequently functioned.
use between centers, with use more prevalent in largerUse of, and the indication for, antibody therapy were
centers (Fig. 2).collected throughout the period (1993 to 2001).
Information about CsSpA use at the time of trans-Proportions are compared with 2 tests, with 95% con-
plantation was missing for 42/3913 (1%) grafts. Of thefidence intervals shown for odds ratios (OR) [5]. Strati-
2293 (57%) grafts where CsSpA use was recorded asfied analyses used Mantel-Haenszel adjustment. A P
used at transplantation, 2058 (90%) were still usingvalue of 0.05 was used as the indicator of statistical sig-
CsSpA at one month. Of those grafts surviving to fivenificance. Uni- and multivariate analyses of factors asso-
years, 516 of 606 (86%) of those initially on CsSpAciated with survival outcome were performed using Cox
remained on CsSpA.(proportional hazards) regressions, and hazard ratios in-
cluding 95% confidence intervals (CI) are shown. Stan- Associates of CsSpA use
dard errors for survival analyses were calculated using
Cyclosporine-sparing agents use varied in association
robust variance estimators [6] clustered on transplant
with a number of parameters (Table 1). CsSpA recipients
center, which relaxes the assumptions of independence
were more likely to be LD recipients, Maori or Pacific
between centers. For logistic regression analyses, stan- Islander, younger or diabetic (type 1). They were less
dard errors were calculated using analogous procedures likely to be Aboriginal or CMV seropositive at time of
[7, 8]. In the creation of multivariate models, all of the transplantation. CD recipients who received CsSpA
variables significant in univariate analysis were inserted were less likely to have nil DR mismatches, but had
into a Cox regression model (for survival outcomes) or shorter ischemic times and time on dialysis pre-trans-
a logistic regression model (for DGF as an outcome). The plantation. Although those receiving grafts from living
goodness-of-fit of the multivariate models was assessed donors were more likely to receive CsSpA in both “rou-
using the Akaike Information Criterion (AIC) [9]. Vari- tine” and “non-routine” hospitals, there was significant
ables were dropped if the P value of the variable was heterogeneity in this association (OR 1.2, 95% CI 1.0 to
0.20 and the dropping did not increase the value of 1.5, for routine hospitals; OR 2.3, 95% CI 1.3 to 4.1, for
the AIC for that model. non-routine hospitals; Mantel-Haenszel 2  4.2, P 
The effects of specific subgroups that might bias the 0.04). Those transplanted in the “routine” CsSpA hospi-
outcome by their inclusion were assessed by comparing tals were significantly more likely to have type 1 (OR
the effect of CsSpA in models before and after their 2.0, 95% CI 1.4 to 2.8, P  0.001), or type 2 diabetes
exclusion. Those groups examined were: transplants per- (OR 1.7, 95% CI 1.3 to 2.2, P  0.002).
formed in very large centers or small centers, Aboriginal There was no significant difference in the prevalence
or Maori recipients, older recipients (45 or 55 years) of coronary artery disease (ascertained at ESRD entry)
and concurrent sirolimus. Sirolimus was only available between the groups (Table 1). Aboriginal recipients (N
in this time period as a part of randomized trials, where 116) were significantly less likely than all other racial
groups to receive CsSpA (OR 0.44, 95% CI 0.30 to 0.65,diltiazem was excluded by the trial protocol.
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Fig. 1. Prevalence of cyclosporine-sparing
agent (CsSpA) use by year of graft operation.
Symbols are: ( ) CsSpA; () no CsSpA.
Fig. 2. Activity of each transplanting unit in
Australia and New Zealand during study pe-
riod, showing number of recipients of CsSpA.
Symbols are ( ) CsSpA; () no CsSpA.
P  0.0001), while, in contrast, Maori/Pacific Islander iod, the HR for graft loss associated with diltiazem use
was 0.43, 95% CI 0.21 to 0.86, P  0.02. For the periodrecipients were more likely to receive CsSpA (OR 2.11,
95% CI 1.5 to 3.1, P  0.0001). The age of donors for after 30 days, there was no difference in graft loss associ-
ated with diltiazem use (HR 1.0, 95% CI 0.78 to 1.3,cadaveric grafts did not differ significantly between re-
cipients of CsSpA and non-recipients overall, but donors P  1.0).
Graft survival (censored for patient death) was pre-were significantly older among recipients of CsSpA in
“routine” hospitals (39.2, 95% CI 38.3 to 40.0, vs. 36.4, dicted by a number of factors: CMV seropositivity, first
vs. subsequent graft, older recipient and donor age, HLA95% CI 34.9 to 37.9, years; t  3.1, P  0.002).
mismatches, race, dialysis duration, and ischemic time.
Graft survival (censored for death) After adjustment for these factors, CsSpA use was still
associated with a reduced risk of graft failure in the firstThere was no significant association of graft survival
(censored for patient death) with CsSpA use among LD 30 days (adjusted HR 0.40, 95% CI 0.20 to 0.78, P 
0.008).recipients.
There was a trend toward a graft survival advantage
Patient survival (censored for graft loss)associated with CsSpA use observed for CD recipients
(Fig. 3). This difference was seen in the very early post- Among LD recipients, there were few deaths in either
group (14 in CsSpA group, 12 in non-diltiazem group)transplant period, after which time the survival curves
are similar in slope. For CD in the 0 to 30 day per- and no significant difference in mortality. Although the
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Table 1. Comparison of cyclosporine-sparing agent (CsSpA) recipients with non-recipients
CsSpA No CsSpA
(N  2293) (N  1578)
“Non-routine” hospital 64 908
“Routine” hospital 2229 670
LDc % all grafts 642 (28%) 364 (23%)
First graft 1994 (87%) 1370 (87%)
Male 1402 (61%) 920 (58%)
Recipient agec years (95% CI) 43.4 (42.8–43.9) 44.8 (44.2–45.3)
Older 55 years 499 (22%) 422 (27%)
Race
Aboriginalc 46 (2%) 72 (5%)
Maori/PIc 136 (6%) 44 (3%)
CMV IgGbc 1473/2227 (66%) 1100/1517 (73%)
Coronary artery disease 293 (13%) 205 (13%)
Any vascular disease 378 (16%) 262 (17%)
Diabetesc
Type 1 108/2259 (5%) 51/1536 (3%)
Type 2 130 (6%) 87 (6%)
Cadaveric grafts
HLA mismatches
Nil 73 (4%) 61 (5%)
1–2 646 (39%) 495 (41%)
3 929 (56%) 657 (54%)
HLA-DR mismatchesc
Nil 724 (44%) 674 (57%)
1 632 (38%) 327 (26%)
2 292 (17%) 212 (17%)
Age of CD recipients years (mean) (95% CI) 45.1 (44.5–45.7) 46.9 (46.7–47.9)
Time on dialysis pre-transplant years (95% CI) 2.5 (2.4–2.6) 3.0 (2.9–3.2)
Ischemic time hours (mean) (SEM) 15.60.13 16.10.14
Donor age years 39.1 (38.3–40.0) 38.5 (37.5–39.5)
Donors 55 years 353 (21%) 255 (21%)
Abbreviations are: LD, living donor; CMV, cytomegalovirus; CD, cadaveric donor.
a P  0.05, bP  0.01, cP  0.001
Fig. 3. Kaplan-Meier curves for graft survival (censored for patient Fig. 4. Patient survival of CD recipients by CsSpA use at time of trans-
plantation. The vertical line indicates one year after transplantation.death) for cadaveric donor (CD) recipients with and without diltiazem.
thereafter (Fig. 4). In the CD group, use of diltiazeminteraction term of diltiazem use and graft type did not
was associated with a patient survival advantage fromreach statistical significance, further patient survival
12 months (HR 0.56, 95% CI 0.41 to 0.76, P  0.001).analyses were restricted to CD recipients only.
Absolute death rates showed a difference of 1.5% perThe Kaplan-Meier curves for patient survival for CD
year to the diltiazem group after 12 months (Table 2).recipients suggest the association of CsSpA with out-
Within “routine” hospitals the survival advantage (fromcome varied with time. Little difference in mortality was
seen over the first year, but a steady difference occurred 1 year post-transplantation) was similar to the overall
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Table 3. Highest grade of biopsy proven cellular rejection by CsSpATable 2. Death rates (per 100 patient-years) for CD recipients by
time period post-transplantation use in all grafts (CD & LD)
Cellular rejection CsSpA No CsSpAGroup 0–12 months 12 months
grade (N  1211) (N  787) OR (95% CI)
CsSpA recipients 2.73 (1.99–3.73) 1.32 (1.01–1.71)
Non-CsSpA recipients 2.13 (2.21–4.42) 2.84 (2.23–3.51) No rejection 885 (73%) 555 (71%)
0.75 (0.54–1.03),
Mild 162 (13%) 136 (17%) P  0.08
0.91 (0.67–1.23),
Moderate 121 (10%) 83 (11%) P  0.6figures (HR 0.45, 95% CI 0.35 to 0.68, P 0.001). Within
2.1 (1.16–3.72)
the “non-routine” hospitals however there was no sig- Severe 43 (4%) 13 (2%) P  0.01
nificant difference in mortality between CsSpA recipi- Odds ratios (OR) are for comparison with the no rejection group, with 95%
CI calculated on “robust” standard errors.ents and non-CsSpA recipients (HR 1.05, 95% CI 0.25
to 4.36, P  0.9). Patient survival among non-CsSpA
CD recipients did not differ whether they were from a
non-routine or routine hospital (HR 1.05, 95% CI 0.69
0.71 (0.60 to 0.84; P  0.0001). This relationship did notto 1.59, P  0.8 for routine hospitals).
differ between LD and CD recipients.There was no association between mortality and cessa-
tion of CsSpA overall or at any individual time. Delayed graft function episodes
Patient mortality in univariate analysis was also pre-
Delayed graft function (as defined) occurred in 555dicted by the presence of vascular disease at ESRD entry,
of 3788 (15%) recipients, significantly less commonlytype 2 diabetes, recipient age, race, CMV status, dialysis
among LD recipients (OR 0.16, 95% CI 0.11 to 0.23,duration pre transplant (for CD1), donor age, ischemic
P  0.001). In CD recipients, delayed graft functiontime and diabetic nephropathy (as native renal disease).
was significantly less common among those who receivedDiltiazem use was included with these factors in a multi-
CsSpA (OR 0.61; 95% CI 0.50 to 0.75, P  0.0001).variate analysis, and after adjustment the effect size re-
This difference was less marked when restricted to themained similar (adjusted HR  0.56, 95% CI 0.40 to
“routine” hospitals (228/1486 vs. 82/416; OR 0.74, 95%0.79, P 0.001). Potential sources of bias were examined
CI 0.55 to 0.99, P  0.03) or the “non-routine” hospitalsby examining the effects of exclusion of key groups [cen-
(1.09, 95% CI 0.46 to 2.39). The variation, however, wasters 25 grafts/year, the largest 2 centers (separately
not statistically significant (Mantel-Haenszel adjustedand together), concurrent sirolimus and older recipients
OR 0.76, 0.59 to 0.97; P  0.03; heterogeneity 2  2.4,(55 years and45 years), Aboriginal recipients, Maori/
P  0.12). A multiple logistic regression analysis wasPacific Islander recipients]. There was no change in the
carried out incorporating the significant predictors ofHR from these changes. The association of mortality
DGF (male sex, any vascular disease, race, dialysis dura-beyond one year with CsSpA use was similar when differ-
tion, donor age, ischemic time, peak PRA category).ent transplant periods were considered (1993-95, 1996-
After controlling for all these factors in a logistic regres-98 and 1999-2001).
sion, the OR for DGF associated with CsSpA use was
Rejection episodes 0.63 (95% CI 0.44 to 0.92, P  0.02) (SE adjusted for
clustering on transplant center).A total of 1998 grafts were performed in the period
when rejection data were collected; 1075 rejection epi-
sodes were reported for 721 people, 469 of whom were
DISCUSSIONCD recipients.
The use of cyclosporine-sparing agents is prevalentThe use of CsSpA drugs was not associated with any
across Australia and New Zealand, with rates rising rap-difference in the prevalence of overall rejection or biopsy
idly from its introduction in the late 1980s to about halfproven rejection in either CD or LD recipients. There
of all grafts performed from 1993. In crude analysis,was significant variation in the reported severity of cellu-
CsSpA use is associated with a patient survival advantagelar rejection between CsSpA use, but no overall differ-
from 12 months post-transplantation. There is also anence in frequency (Table 3). The occurrence of at least
association with lower graft loss in the immediate post-one episode of vascular rejection was reported in 162
transplant period. In multivariate analysis both the effectgrafts, but neither the occurrence nor severity of vascular
on patient survival and early graft survival are indepen-rejection was associated with CsSpA use.
dent of those potential confounders that are collectedCsSpA use was associated with lower rates of antibody
by the Registry.use for rejection: 352 of 2293 (15%) CsSpA recipients
The present analysis focuses on those in whom CsSpAreceived antibody therapy for this reason versus 321 of
use was reported at the time of transplantation, and is1578 (26%) among CsSpA non-recipients. The OR for
antibody use for rejection associated with CsSpA was thus analogous to an “intent-to-treat” analysis. Diltiazem
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is well tolerated, with low cessation rates. The reasons available to confirm this observation. Although exclusion
of Aboriginal and Maori/Pacific Isander recipients re-for cessation where it occurs are, however, unknown. In
some cases these might be expected to bias results (for duces the number of end points, the effect size (that is,
HR) is unchanged. Another influence is trials of newerexample, if diltiazem were ceased due to hypotension
or bradyarrhythmias), but other adverse effects such as immunosuppressive agents. Where these do not involve
cyclosporine, they might bias a center’s results by exclud-constipation are less likely to bias mortality outcome.
The association between diltiazem use and rejection ing lower risk patients from receiving cyclosporine-based
immunosuppression and hence inclusion in this cohort.is less clear than that with mortality. While an association
of diltiazem with lower rejection rates is suggested by Further potential bias arises from the trials that com-
pared various sirolimus/cyclosporine combinations. Dil-the association with lower rates of antibody use, this is
not supported by the reports of biopsy data or of the tiazem use was excluded by the trial protocol. This might
bias lower risk recipients toward to the non-CsSpA group,trends to more severe cellular rejection. Other factors
also might influence this observation, including differ- but exclusion of this group did not affect the overall result.
Although known confounders have been included asences between hospitals in propensity to utilize antibody
therapy, and differences in coding of biopsy reports. The controlling factors in the multivariate analysis, this is an
imperfect process. As well as issues such as the choice ofdifference in patient survival persists despite controlling
for age, co-morbidity and other factors, and continues the statistical method of adjustment, post-hoc adjustment
(in contrast to randomization) can only account for knownover a different and much longer period than the associa-
tion with graft failure. This suggests a different explana- confounding factors. The validity of the adjustment pro-
cess is limited by the accuracy of measurement of thetion for this association to that for the association with
early graft loss. The three major causes of death in the confounders. In the ANZDATA survey data included
here, co-morbid prevalence has been ascertained as anpost-transplant setting are cancer, infection and cardio-
vascular disease. The most plausible scenario involves opinion of the treating physician at the commencement
of ESRD treatment. The severity of disease is not known,reduction in the last. Possible mechanisms for the action
of diltiazem include better blood pressure control or the nor are differences in practice between transplanting cen-
ters with respect to severity of co-morbid disease neededcytoprotective effect postulated to affect the recovering
kidney extending to cardiac myocytes or vascular endo- to preclude transplantation. The validity of this informa-
tion is currently being improved, as ANZDATA has re-thelial or subendothelial cells.
Although some have alluded to an immunosuppres- cently begun to collect information on current preva-
lence of co-morbidities (as well as the previous practicesive effect of diltiazem as cause of reduced usage of
antibody therapy for rejection [2], others have suggested of noting these at ESRD entry).
The effect of controlling for confounding is crucialthis is mediated by alterations in cyclosporine metabo-
lites rather than a direct diltiazem effect [4]. Diltiazem to the results of this study. The statistical methods are
conservative in the use of “robust” standard error foralso has a vasodilatory effect that might reduce the renal
vasospasm seen with cyclosporine. Inhibition of this va- the survival analyses, which should help avoid the danger
of spurious associations related to a “center effect” [12].sospasm has been demonstrated for nifedipine [10] and
lacidipine [11], although these agents have a much lesser Whether such as effect exists in Australia is not clear
at present. The use of such techniques to account foreffect on cyclosporine metabolism. It is conceivable that
similar effects might occur on systemic vessels, and diltia- potential clustering of results in centers is rapidly grow-
ing [13]. However, it does raise further questions, partic-zem might ameliorate the systemic hypertensive effect
of cyclosporine. Whether the effect of diltiazem is associ- ularly about whether the original transplanting center
is the appropriate stratifying variable for longer termated with benefit in the absence of cyclosporine is un-
known. outcomes, since many recipients subsequently return to
their referring hospital for follow-up care or relocate forThere is substantial and unexplained variation in sev-
eral key parameters between the comparison groups, in other reasons.
Our results suggest a survival advantage for thosethe selection of which patients receive CsSpA and differ-
ences between “routine” and “non-routine” hospitals. given diltiazem, and an association with reduced delayed
graft function and possibly less early graft loss. The sizeThere are no data available in the Registry about why
CsSpA use was chosen in individual cases, but several of the effect is large enough to be clinically significant.
Although the statistical techniques will adjust for knownpossibilities can be considered. CsSpA use might be in-
fluenced (in either direction) by consideration of blood effects, they cannot account for unknown or unmeasured
variables. A cohort with more detailed information (pref-pressure and cardiac history. Anecdotally, the lower rate
of use among Aboriginal graft recipients has been attrib- erably collected prospectively) in areas such as blood pres-
sure and severity of coronary artery disease would allowuted to suspected differences in pharmacokinetics and
possibly pharmacodynamics, but no published data are better definition of reasons for use and associated co-
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renal allograft recipients receiving cyclosporine. Transplantationmorbidities. A randomized controlled trial, however, re-
55:300–304, 1993
mains the optimal design to further examine the hypoth- 3. Carmellini M, Salvadori M, Di Stefano R, et al: Delayed graft
function of cadaveric renal transplants is prevented by diltiazem.esis that diltiazem is responsible for the improved out-
Transplant Proc 28:80–82, 1996comes rather than acting as a marker of other factors 4. Kunzendorf U, Walz G, Brockmoeller J, et al: Effects of diltia-
that influence outcome. zem upon metabolism and immunosuppressive action of cyclospo-
rine in kidney graft recipients. Transplantation 52:280–284, 1991
5. Cornfield J: A statistical problem arising from retrospective stud-
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